Prexton closes €8.7 million ($10 million) in Series A financing to develop treatments for Parkinson’s

Prexton Therapeutics, a biopharmaceutical company developing novel therapeutic compounds for the treatment of CNS conditions including Parkinson’s disease, today announces the closing of a Series A financing of €8.7 million ($10 million) co-led by Sunstone Capital and Ysios Capital.



from The Medical News http://ift.tt/1DsOikA